S.Biomedics Co., Ltd. (KOSDAQ:304360)

Market Cap	389.51B +61.0%
Revenue (ttm)	16.48B +5.7%
Net Income	-8.22B
EPS	-683.17
Shares Out	12.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	146,370
Open	30,250
Previous Close	29,800
Day's Range	29,500 - 33,250
52-Week Range	17,930 - 42,600
Beta	1.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About S.Biomedics

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2005
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 304360

Financial Performance

In 2025, S.Biomedics's revenue was 16.55 billion, an increase of 20.49% compared to the previous year's 13.73 billion. Losses were -8.12 billion, 21.4% more than in 2024.